A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
Conclusion Carboplatin plus weekly paclitaxel with bevacizumab is a feasible, effective first-line regimen for elderly non-small cell lung cancer patients. (UMIN00006622).
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cardiology | Congestive Heart Failure | Diabetes | Drugs & Pharmacology | Endocrinology | Heart | Heart Failure | Hypertension | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology